Formulation and specifications: Injection: 120mg (2.4ml)/bottle, 500mg (10ml)/bottle
Indications:.
1. Duvacizumab is indicated for the treatment of unresectable, stage III NSCLC patients who have not experienced disease progression after receiving simultaneous platinum-based chemotherapy with radiotherapy.
2. dulvalizumab in combination with etoposide and carboplatin or cisplatin for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).
Key points for rational drug use:
1. unresectable stage III NSCLC: dulvalizumab is administered at 10 mg/kg by intravenous infusion every 2 weeks, with each infusion taking longer than 60 minutes until disease progression or intolerable toxicity occurs. The maximum duration of use is not to exceed 12 months.
2. ES-SCLC: 1500 mg of dulvalizumab in combination with etoposide and carboplatin or cisplatin every 3 weeks for 4 cycles, followed by 1500 mg every 4 weeks as monotherapy until disease progression or intolerable toxicity occurs. Patients weighing 30 kg or less must receive weight-based dosing of dulvalizumab 20 mg/kg in combination with chemotherapy every 3 weeks for 4 cycles, followed by 20 mg/kg every 4 weeks as monotherapy until weight gain to >30 kg.
3. For suspected immune-related adverse reactions, an adequate evaluation should be performed to confirm the etiology or to exclude other etiologies. Depending on the type and severity of the immune-related adverse reaction, dosing should be suspended or permanently discontinued, and no dose increase or decrease is recommended.
4. The safety and efficacy of dulvalizumab in children and adolescents under 18 years of age have not been established. No dose adjustment is required in elderly patients (≥65 years of age), patients with mild hepatic impairment, or patients with mild to moderate renal impairment. The safety and efficacy of use in patients with moderate to severe hepatic impairment and patients with severe renal impairment have not been established and should be used with caution under the guidance of a physician if the expected benefit of using this product outweighs the risk as assessed by the physician.